Sarepta shares drop as report says FDA almost rejected under-review gene therapy
(Reuters) – Sarepta Therapeutics Inc’s shares fell as much as
sarepta
Sarepta slides as FDA about-turn on panel clouds gene therapy approval path
By Aditya Samal (Reuters) -Shares of Sarepta Therapeutics Inc slumped